Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Intern Med ; 60(2): 231-234, 2021 Jan 15.
Article in English | MEDLINE | ID: covidwho-1067518

ABSTRACT

Cancer patients are regarded as highly vulnerable to severe acute respiratory syndrome coronavirus (SARS-CoV)-2. However, little is known regarding how cancer treatments should be restarted for cancer patients after coronavirus disease (COVID)-19. We herein report a pancreatic cancer case in which chemotherapy was able to be reinstituted after COVID-19. The patient was a 67-year-old man diagnosed with pancreatic cancer. On day 7 after first chemotherapy, he was infected with COVID-19. A SARS-CoV-2 test was negative after one month of treatment, and we reinstituted chemotherapy. The patient has received three cycles of chemotherapy without recurrence of COVID-19. It may be feasible to reinstitute chemotherapy for cancer patients after a negative SARS-CoV-2 test.


Subject(s)
Antineoplastic Agents/therapeutic use , COVID-19/diagnosis , Pancreatic Neoplasms/drug therapy , SARS-CoV-2 , Aged , COVID-19/complications , COVID-19/diagnostic imaging , Diagnosis, Differential , Drug Administration Schedule , Humans , Male , Pancreatic Neoplasms/complications , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL